/

Empresas

Al

No verificado

Alchemab Therapeutics

Sobre qué escribimos

BiologíaCienciaEconomíaFarmacéuticaSanidad

6 Comunicados de prensa

Ver todos los comunicados de prensa

09/07/2026

Mercado laboral

Industria

Técnica

Biotecnología

Salud

Finanzas

Farmacéutica

Asociaciones/Profesionales

Ciencia

Sanidad

Medicina - Varios

Alchemab Therapeutics Announces Largest Ever Life Sciences Investment From British Business Bank to Advance AI-Enabled Clinical Pipeline of Next Generation Human-Derived Antibodies

Fuente

Alchemab Therapeutics

Editor

1.00

0

17/03/2026

Ulrich Wendt joins UK biotech Alchemab Therapeutics as Chief Business Officer to expand biopharma partnerships

Fuente

Alchemab Therapeutics

Editor

1.00

0

06/05/2025

Farmacéutica

Sanidad

Empresas

Administración de Empresas

Biología

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company

Fuente

Alchemab Therapeutics

Editor

1.00

0

09/01/2025

Farmacéutica

Sanidad

Biología

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

Fuente

Alchemab Therapeutics

Editor

1.00

0

12/09/2024

Farmacéutica

Tecnología de la información

Telecomunicaciones

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Biología

Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

Fuente

Alchemab Therapeutics

Editor

1.00

0

06/06/2024

Farmacéutica

Sanidad

Economía

Start-up

Biología

Alchemab advances a novel antibody with potential in Parkinson's disease with support from The Michael J. Fox Foundation

Fuente

Alchemab Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0